Long-term sustained improvement in symptoms of benign prostatic hyperplasia with the dual 5alpha-reductase inhibitor dutasteride: results of 4-year studies.

Claus Roehrborn, Olavi Lukkarinen, Stephen Mark, Paul F. Siami, Joe Wesley Ramsdell, Norman R. Zinner
Published 2005 in BJU international

Abstract

OBJECTIVE To report additional analyses of efficacy over the initial 2 years and during a 2-year open-label extension of the three pivotal phase 3 studies in which dutasteride, a dual inhibitor of type 1 and 2 5alpha-reductase, was shown to be effective and well tolerated. PATIENTS AND METHODS All patients in the placebo and active groups were eligible… (More)

Long-term Combination Therapy With α-Blockers and 5α-Reductase Inhibitors in Benign Prostatic Hyperplasia: Patient Adherence and Causes of Withdrawal From Medication

Hueih Ling Ong, Chun-Hou Liao, Hann-Chorng Kuo
International neurourology journal
2016

Long-term sustained improvement in symptoms of benign prostatic hyperplasia with the dual 5alpha-reductase inhibitor dutasteride: results of 4-year studies.

Abstract

Topics

Figures and Tables

Cited By

Experience with the combination of dutasteride and tamsulosin in the long-term management of benign prostatic hyperplasia.

Long-term Combination Therapy With α-Blockers and 5α-Reductase Inhibitors in Benign Prostatic Hyperplasia: Patient Adherence and Causes of Withdrawal From Medication

Lessons learned about prostatic transformation from the age-related methylation of 5α-reductase type 2 gene.

Short-term pretreatment with a dual 5α-reductase inhibitor before bipolar transurethral resection of the prostate (B-TURP): evaluation of prostate vascularity and decreased surgical blood loss in large prostates.

Clinical Effects of Discontinuing 5-Alpha Reductase Inhibitor in Patients With Benign Prostatic Hyperplasia

Guidelines on the Management of Non-Neurogenic Male Lower Urinary Tract Symptoms (LUTS), incl. Benign Prostatic Obstruction (BPO)

EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction.

Systematic review evaluating cardiovascular events of the 5-alpha reductase inhibitor - Dutasteride.

Clinical Medicine Insights: Therapeutics

Alpha-blockers and intraoperative floppy iris syndrome: ophthalmic adverse events following cataract surgery.

References

Slides referencing similar topics

Long-term sustained improvement in symptoms of benign prostatic hyperplasia with the dual 5alpha-reductase inhibitor dutasteride: results of 4-year studies.

Abstract

Topics

Figures and Tables

Cited By

Experience with the combination of dutasteride and tamsulosin in the long-term management of benign prostatic hyperplasia.

Long-term Combination Therapy With α-Blockers and 5α-Reductase Inhibitors in Benign Prostatic Hyperplasia: Patient Adherence and Causes of Withdrawal From Medication

Lessons learned about prostatic transformation from the age-related methylation of 5α-reductase type 2 gene.

Short-term pretreatment with a dual 5α-reductase inhibitor before bipolar transurethral resection of the prostate (B-TURP): evaluation of prostate vascularity and decreased surgical blood loss in large prostates.

Clinical Effects of Discontinuing 5-Alpha Reductase Inhibitor in Patients With Benign Prostatic Hyperplasia

Guidelines on the Management of Non-Neurogenic Male Lower Urinary Tract Symptoms (LUTS), incl. Benign Prostatic Obstruction (BPO)

EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction.

Systematic review evaluating cardiovascular events of the 5-alpha reductase inhibitor - Dutasteride.

Clinical Medicine Insights: Therapeutics

Alpha-blockers and intraoperative floppy iris syndrome: ophthalmic adverse events following cataract surgery.

References

Similar Papers

Slides referencing similar topics